Want to see DE:M12 full AI Analyst Report?

M1 Kliniken AG (M12) Price & Analysis

13 Followers

M12 Stock Chart & Stats

€18.16

-€0.10(-0.64%)

At close: Jan 09 4:00 PM EST

€18.16

-€0.10(-0.64%)

Day’s Range― - ―

52-Week Range€12.78 - €20.00

Previous CloseN/A

Volume462.00

Average Volume (3M)13.86K

Market Cap

€338.07M

Enterprise Value€321.02M

Total Cash (Recent Filing)€42.00M

Total Debt (Recent Filing)€10.26M

Price to Earnings (P/E)15.1

Beta0.34

Next Earnings

Sep 09, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend Yield2.8%

Share Statistics

EPS (TTM)1.20

Shares Outstanding19,643,402

10 Day Avg. Volume17,849

30 Day Avg. Volume13,861

Financial Highlights & Ratios

PEG Ratio0.42

Price to Book (P/B)2.94

Price to Sales (P/S)0.97

P/FCF Ratio9.32

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)1.04

Revenue Forecast (FY)€134.38M

Bulls Say, Bears Say

Bulls Say

Strong Cash GenerationSustained operating and free cash flow growth shows durable cash conversion from patient-paid services and product sales. Reliable internal cash generation supports reinvestment in clinics, equipment, dividends or M&A, and lowers dependency on external financing over multiple quarters.

Conservative Balance Sheet / Low LeverageVery low leverage and rising equity provide financial resilience and flexibility. A conservative capital structure reduces interest burden, supports investment in organic growth or acquisitions, and helps the company withstand elective-care cyclical downturns without stressing liquidity.

Consistent Revenue Growth And Rising ProfitsSteady top-line growth coupled with materially higher net income indicates durable demand for elective aesthetic services and improved operating leverage. Persistent revenue and earnings expansion strengthen the firm's ability to fund expansion, improve margins, and sustain shareholder returns.

Bears Say

Margin Volatility / Limited 2025 Margin DetailNotable swings in gross and EBITDA margins across 2023–2024 and sparse 2025 margin disclosure reduce visibility into sustainable profitability. For an elective-services model sensitive to procedure mix and supplier pricing, persistent margin volatility complicates long-term planning and capital allocation.

Historical Cash-flow Volatility (2023 Trough)A severe operating cash flow dip in 2023 shows cash generation can swing materially, which can strain funding for CapEx, clinic openings, or dividends during weak periods. Such cyclicality may necessitate larger liquidity buffers or flexible financing to sustain medium-term growth plans.

Asset Base Dip 2023–2024A decline in total assets despite equity growth raises questions about reinvestment pace into clinics or asset disposals. If the asset base is not rebuilt, capacity constraints could limit patient throughput and revenue scaling, constraining longer-term growth potential.

M12 FAQ

What was M1 Kliniken AG’s price range in the past 12 months?

M1 Kliniken AG lowest stock price was €12.78 and its highest was €20.00 in the past 12 months.

What is M1 Kliniken AG’s market cap?

M1 Kliniken AG’s market cap is €338.07M.

When is M1 Kliniken AG’s upcoming earnings report date?

M1 Kliniken AG’s upcoming earnings report date is Sep 09, 2026 which is in 58 days.

How were M1 Kliniken AG’s earnings last quarter?

Currently, no data Available

Is M1 Kliniken AG overvalued?

According to Wall Street analysts M1 Kliniken AG’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does M1 Kliniken AG pay dividends?

M1 Kliniken AG pays a Annually dividend of €1.2 which represents an annual dividend yield of 2.8%. See more information on M1 Kliniken AG dividends here

What is M1 Kliniken AG’s EPS estimate?

M1 Kliniken AG’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does M1 Kliniken AG have?

M1 Kliniken AG has 19,643,402 shares outstanding.

What happened to M1 Kliniken AG’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of M1 Kliniken AG?

Currently, no hedge funds are holding shares in DE:M12

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

M1 Kliniken AG Stock Smart Score

Neutral

Technicals

Fundamentals

Return on Equity

18.60%

Trailing 12-Months

Asset Growth

0.75%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

M1 Kliniken AG

M1 Kliniken AG, a Berlin, Germany-based entity established in 2007 and operating as a subsidiary of MPH Health Care AG, manages medical facilities dedicated to aesthetic and plastic surgery across Germany, Austria, the Netherlands, Switzerland, the United Kingdom, Croatia, and Australia. The company's operations are segmented into two core divisions: Beauty and Trade. The Beauty segment is responsible for the creation and commercialization of pharmaceutical, medical, and medical technology products tailored for aesthetic medicine and cosmetic dermatology. Meanwhile, the Trade segment engages in the distribution of pharmaceuticals, biosimilars, and other medical products and devices, serving critical therapeutic areas such as oncology, HIV, rheumatology, neurology, cardiovascular conditions, and narcotics. Products are supplied to healthcare professionals, pharmacies, and wholesale distributors under the "M1 Select" brand. M1 Kliniken AG's operational footprint encompasses a network of outpatient specialist centers, a specialized surgical clinic center, and 46 distinct specialist locations branded as "M1 Med Beauty." Additionally, the company is involved in the acquisition, administration, and divestiture of real estate, predominantly within the healthcare industry.